Literature DB >> 31752010

Gastrodin Alleviates Vascular Dementia in a 2-VO-Vascular Dementia Rat Model by Altering Amyloid and Tau Levels.

Rui Shi1,2, Chang-Bo Zheng1, Hongyan Wang1, Qiang Rao1, Tingyan Du1, Chunyun Bai1, Chuang Xiao1, Zelan Dai1, Changhong Zhang1, Chen Chen1, Xian Li1, Menghua Tian3, Xianlun Yu3, Baixi Ji1, Zhiying Weng1, Weimin Yang4.   

Abstract

Vascular dementia (VaD) is the second most common type of dementia and has become a major public health challenge as the global population ages. VaD is caused by cerebrovascular disease, and most patients with VaD have been reported to also have Alzheimer's pathologies, which is the formation of neurofibrillary tangles and amyloid plaques that are mainly composed of hyperphosphorylated Tau and amyloid β (Aβ) respectively. However, the mechanisms of VaD are not completely understood, and very few drugs are available to treat this condition. Gastrodin (Gas) is the main bioactive component of the traditional Chinese herbal plant named Tian Ma (Gastrodia elata), and it has been used to treat neurasthenia in the clinical practice of Chinese Medicine for many years. Here, we hypothesize that Gas alleviates VaD in a rat model of permanent bilateral common carotid artery occlusion (2-VO)-induced VaD. Based on the results of the Morris water maze test and attention set shift test, either 22.5 or 90 mg/kg/day Gas improved the executive dysfunction and memory impairment of 2-VO rats following an intragastric administration for 4 weeks. Both 22.5 and 90 mg/kg/day Gas reduced Aβ1-40 and Aβ1-42 plaques in plasma and hippocampus of 2-VO rats. Mechanistically, in 2-VO rats, treatment with Gas (90 mg/kg/day) suppressed Aβ plaque deposition by decreasing the hippocampus levels of phosphorylated Tau. Thus, Gas ameliorated the cognitive deficits of 2-VO rats by inhibiting the abnormal phosphorylation of Aβ and Tau.
© 2019 S. Karger AG, Basel.

Entities:  

Keywords:  2-VO-vascular dementia; Amyloid β; Gastrodin; Tau; Vascular dementia

Mesh:

Substances:

Year:  2019        PMID: 31752010     DOI: 10.1159/000504056

Source DB:  PubMed          Journal:  Pharmacology        ISSN: 0031-7012            Impact factor:   2.547


  4 in total

1.  Effects of Gastrodin against Lead-Induced Brain Injury in Mice Associated with the Wnt/Nrf2 Pathway.

Authors:  Chan-Min Liu; Zhi-Kai Tian; Yu-Jia Zhang; Qing-Lei Ming; Jie-Qiong Ma; Li-Ping Ji
Journal:  Nutrients       Date:  2020-06-17       Impact factor: 5.717

2.  Preventive Electroacupuncture Ameliorates D-Galactose-Induced Alzheimer's Disease-Like Pathology and Memory Deficits Probably via Inhibition of GSK3β/mTOR Signaling Pathway.

Authors:  Chao-Chao Yu; Jia Wang; Si-Si Ye; Shan Gao; Jia Li; Li Wang; Tao Jiang; Xue-Song Wang; Bo-Cun Li; Qing Shu; Wei Lu; Yan-Jun Du; Li-Hong Kong
Journal:  Evid Based Complement Alternat Med       Date:  2020-04-23       Impact factor: 2.629

Review 3.  Gastrodin and Vascular Dementia: Advances and Current Perspectives.

Authors:  Chujun Deng; Huize Chen; Zeyu Meng; Shengxi Meng
Journal:  Evid Based Complement Alternat Med       Date:  2022-04-12       Impact factor: 2.650

4.  Gastrodin Exerts Cardioprotective Action via Inhibition of Insulin-Like Growth Factor Type 2/Insulin-Like Growth Factor Type 2 Receptor Expression in Cardiac Hypertrophy.

Authors:  Jun Lu; Xin Ma; Wen-Cong Gao; Xin Zhang; Yuanling Fu; Qian Liu; Lixiang Tian; Xiao-Dan Qin; Weimin Yang; Hong-Yi Zheng; Chang-Bo Zheng
Journal:  ACS Omega       Date:  2021-06-21
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.